COVID-19: can we treat the mother without harming her baby?

Wiese, Michael; Berry, Mary J.; Hissaria, Pravin; Darby, Jack R. T.; Morrison, Janna L.

doi:10.1017/s2040174420001403

Cited by 5 publications

(6 citation statements)

References 144 publications

(155 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Angiotensin converting enzyme 2, a target of SARS-CoV-2 cell entry, and the spike glycoprotein of SARS-CoV2 have been found on the syncytiotrophoblast cells of the placental villi that form the interface between mother and fetus in the placenta. 29 Therefore, vertical transmission may be possible, unlike with SARS, where no evidence of vertical transmission exists, but it is unclear whether these 19 cases were infected in utero, intrapartum or postpartum. 25 This study by Pettirosso et al also states that the risk of vertical transmission was assessed with rtPCR of nasopharyngeal secretions, placenta, cord blood, amniotic fluid and breastmilk.…”

Section: Vertical Transmission Likelihoodmentioning

confidence: 99%

COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review

Joubert

Kekeh

Amin³

2021

BJOG

View full text Add to dashboard Cite

The novel coronavirus, SARS‐CoV‐2, or COVID‐19, has affected the world on a pandemic scale resulting in catastrophic outcomes and deaths. Currently, there is limited safety data specific to mRNA vaccine use in pregnant or lactating individuals and the potential risks to a pregnant individual and the fetus are unknown. We report an updated literature review of current information and evidence available to aid in the decision whether to vaccinate against COVID‐19 currently being made by pregnant individuals and their healthcare providers so that they are able to make a well‐informed recommendation and decision.

show abstract

Section: Vertical Transmission Likelihoodmentioning

confidence: 99%

COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review

Joubert

Kekeh

Amin³

2021

BJOG

View full text Add to dashboard Cite

show abstract

“…Ghema et al [ 18 ] and Crovetto et al [ 35 ] found through their fetal studies other less frequent complications such as perinatal asphyxia, respiratory failure, multi-organ dysfunction, brain damage, malformation, intrapartum fetal distress, and even death. Another complication in children of COVID-19-infected pregnant women, though rare, is a neonatal inflammatory syndrome whose clinical manifestations are elevated inflammatory biomarkers, organ dysfunction, and in some cases myocardial dysfunction [ 33 ].…”

Section: Resultsmentioning

confidence: 99%

“…Studies were also conducted on the breast milk of those mothers who were infected, as breast milk could be a mechanism of transmission to the neonate; however, these indicated that it was the close contact of the neonate with its mother that caused the infection, as no evidence of SARS-CoV-2 RNA or protein was found in breast milk [ 27 ]. However, studies suggest that the mechanisms involved in maternal–fetal transmission are unclear and that transmission is probable, but the incidence is extremely low [ 33 ] and most are acquired at delivery or postpartum [ 25 ].…”

Section: Resultsmentioning

confidence: 99%

COVID-19 in Pregnant Women, Maternal—Fetal Involvement, and Vertical Mother-to-Child Transmission: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Pregnant women are included in the COVID-19 risk groups even if they do not have any pathology. This requires an analysis of research focused on pregnant women to understand the impact of SARS-CoV-2 on their condition. There is also a need to know whether there is vertical mother-to-child transmission, as well as other consequences in case the pregnant woman is infected and COVID-19 positive. A systematic review was carried out to analyze the existing information on the complications of a pregnant woman infected with the SARS-CoV-2 coronavirus and the possibility of vertical transmission from mother to child, registered in the PROSPERO website and searched in the PubMed, Scopus, CINAHL, and Cochrane Library databases. Finally, 22 articles were included in the review. The review suggests that vertical transmission from mother to child could be exceptionally possible at the time of delivery or breastfeeding, but not through the placenta. It is interesting to point out the good acceptance of vaccination by pregnant women, which may be the reason for the low infectivity. Further research on pregnant women should be carried out to provide evidence on vertical mother-to-child transmission and the role of breast milk in relation to SARS-CoV-2.

show abstract

“…Pregnant women are a traditionally poorly represented group in drug studies, but a high-risk group with regard to unwanted maternal-fetal events because of the unique physiology of pregnancy with implications for fetal and neonatal drug exposure. However, given the complexity of participation in drug trials during pregnancy, many clinical drug trials exclude pregnant women [ 46 ].…”

Section: Resultsmentioning

confidence: 99%

Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review

Franchini

Prefumo

Grisolia

et al. 2021

Viruses

View full text Add to dashboard Cite

The treatment of COVID-19 is particularly critical in pregnant women, considering the potential teratogenic effects of antiviral agents and the immune-depression related with pregnancy. The aim of this review is to systematically examine the current evidence on the clinical use of convalescent plasma during pregnancy. The electronic databases Medline PubMed Advanced Search Builder, Scopus, Web Of Science and Google Scholar were searched (until 1 January 2021). Inclusion criteria were pregnant women with COVID-19 (or SARS-CoV-2 infection), in whom convalescent plasma (or hyperimmune plasma) was used as treatment. We searched clinical trial registries (censored 5 January 2021) for eligible studies under way. After elimination of duplications, the initial search yielded 79 potentially relevant records, of which 67 were subsequently excluded. The 12 remaining records were case reports involving 12 pregnancies. Six of the mothers were reported to be well, two were reported to have preeclampsia, and in one case each the maternal outcome was described as survival, clinical improvement, discharged with oxygen and rehabilitation. With regard to the neonates, two were declared to be well, four had transient morbidity, two were critically ill and one died; normal ongoing pregnancies, but no post-delivery information, were reported for the remaining three cases. Clinical trials under way or planned to investigate the use of convalescent plasma for COVID-19 during pregnancy are lacking. This is the first systematic review of the literature regarding the treatment of COVID-19 in pregnancy. The published literature data seem to indicate that convalescent plasma administered to pregnant women with severe COVID-19 provides benefits for both the mother and the fetus. The quality of the available studies is, however, very limited since they are all case reports and thus suffer from relevant reporting bias.

show abstract

COVID-19: can we treat the mother without harming her baby?

Cited by 5 publications

References 144 publications

COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review

COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review

COVID-19 in Pregnant Women, Maternal—Fetal Involvement, and Vertical Mother-to-Child Transmission: A Systematic Review

Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review

Contact Info

Product

Resources

About